GERON CORP Unrealized Gain (Loss) on Derivatives
GERON CORP (GERN) reported Unrealized Gain (Loss) on Derivatives of $16.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2018-03-16
- GERON CORP unrealized gain (loss) on derivatives for the quarter ending 2015-12-31 was $0.00.
- GERON CORP unrealized gain (loss) on derivatives for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- GERON CORP unrealized gain (loss) on derivatives for the quarter ending 2015-06-30 was $0.00.
- GERON CORP unrealized gain (loss) on derivatives for the quarter ending 2015-03-31 was $16.00K, a 92.86% decline year-over-year.
- GERON CORP unrealized gain (loss) on derivatives for fiscal 2015 was $16.00K, a 95.44% decline from fiscal 2014.
- GERON CORP unrealized gain (loss) on derivatives for fiscal 2014 was $351.00K.
- GERON CORP unrealized gain (loss) on derivatives for fiscal 2013 was -$316.00K, a 2530.77% decline from fiscal 2012.
- GERON CORP unrealized gain (loss) on derivatives for fiscal 2012 was $13.00K, a 97.98% decline from fiscal 2011.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $0.00 derived: sum of 3 quarters · filed 2018-03-16 | $16.00K 10-K · filed 2018-03-16 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $16.00K 10-Q · filed 2016-11-03 | $1.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $16.00K 10-Q · filed 2016-08-03 | $1.00K derived: sum of 3 quarters · filed 2017-03-01 | $290.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $16.00K 10-Q · filed 2016-05-05 | $1.00K derived: sum of 2 quarters · filed 2017-03-01 | $290.00K derived: sum of 3 quarters · filed 2017-03-01 | $143.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $274.00K derived: sum of 2 quarters · filed 2017-03-01 | $127.00K derived: sum of 3 quarters · filed 2017-03-01 | $351.00K 10-K · filed 2017-03-01 |
| 2014-09-30 | $289.00K 10-Q · filed 2015-11-05 | $142.00K derived: sum of 2 quarters · filed 2015-11-05 | $366.00K 10-Q · filed 2015-11-05 | $257.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | -$147.00K 10-Q · filed 2015-08-05 | $77.00K 10-Q · filed 2015-08-05 | -$32.00K derived: sum of 3 quarters · filed 2016-03-10 | -$240.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $224.00K 10-Q · filed 2015-05-07 | $115.00K derived: sum of 2 quarters · filed 2016-03-10 | -$93.00K derived: sum of 3 quarters · filed 2016-03-10 | -$117.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | -$109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | -$317.00K derived: sum of 2 quarters · filed 2016-03-10 | -$341.00K derived: sum of 3 quarters · filed 2016-03-10 | -$316.00K 10-K · filed 2016-03-10 |
| 2013-09-30 | -$208.00K 10-Q · filed 2014-11-05 | -$232.00K derived: sum of 2 quarters · filed 2014-11-05 | -$207.00K 10-Q · filed 2014-11-05 | -$184.00K derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-06-30 | -$24.00K 10-Q · filed 2014-08-11 | $1.00K 10-Q · filed 2014-08-11 | $24.00K derived: sum of 3 quarters · filed 2015-03-11 | -$20.00K derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-03-31 | $25.00K 10-Q · filed 2014-05-01 | $48.00K derived: sum of 2 quarters · filed 2015-03-11 | $4.00K derived: sum of 3 quarters · filed 2015-03-11 | $12.00K derived: sum of 4 quarters · filed 2015-03-11 |
| 2012-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | -$21.00K derived: sum of 2 quarters · filed 2015-03-11 | -$13.00K derived: sum of 3 quarters · filed 2015-03-11 | $13.00K 10-K · filed 2015-03-11 |
| 2012-09-30 | -$44.00K 10-Q · filed 2013-11-07 | -$36.00K derived: sum of 2 quarters · filed 2013-11-07 | -$10.00K 10-Q · filed 2013-11-07 | $63.00K derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $8.00K 10-Q · filed 2013-08-08 | $34.00K 10-Q · filed 2013-08-08 | $107.00K derived: sum of 3 quarters · filed 2014-03-17 | $398.00K derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $26.00K 10-Q · filed 2013-05-03 | $99.00K derived: sum of 2 quarters · filed 2014-03-17 | $390.00K derived: sum of 3 quarters · filed 2014-03-17 | $630.00K derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $364.00K derived: sum of 2 quarters · filed 2014-03-17 | $604.00K derived: sum of 3 quarters · filed 2014-03-17 | $643.00K 10-K · filed 2014-03-17 |
| 2011-09-30 | $291.00K 10-Q · filed 2012-11-02 | $531.00K derived: sum of 2 quarters · filed 2012-11-02 | $570.00K 10-Q · filed 2012-11-02 | |
| 2011-06-30 | $240.00K 10-Q · filed 2012-08-03 | $279.00K 10-Q · filed 2012-08-03 | ||
| 2011-03-31 | $39.00K 10-Q · filed 2012-05-07 | |||
| 2010-12-31 | $190.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |